BAKER BROS. ADVISORS LP Q2 2021 Filing
Filed August 16, 2021
Portfolio Value
$22.8T
Holdings
120
Report Date
Q2 2021
Filing Type
13F-HR
All Holdings (120 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 101 | 5E7Iteos Therapeutics, Inc. | 150,346 | $3.9B | 0.02% | |
| 102 | HRMYHarmony Biosciences Holdings, Inc. | 123,600 | $3.5B | 0.02% | |
| 103 | 1T7Tricida, Inc. | 729,300 | $3.2B | 0.01% | |
| 104 | —Evofem Biosciences, Inc. | 2,697,110 | $3.0B | 0.01% | |
| 105 | AKROAkero Therapeutics, Inc. | 118,378 | $2.9B | 0.01% | |
| 106 | —TCR2 Therapeutics Inc. | 176,461 | $2.9B | 0.01% | |
| 107 | XLRNAcceleron Pharma Inc. | 22,430 | $2.8B | 0.01% | |
| 108 | TVTXTravere Therapeutics, Inc. | 186,915 | $2.7B | 0.01% | |
| 109 | RLMDRelmada Therapeutics, Inc. | 76,600 | $2.5B | 0.01% | |
| 110 | —LogicBio Therapeutics, Inc. | 451,478 | $2.0B | 0.01% | |
| 111 | TARAProtara Therapeutics, Inc. | 199,671 | $1.9B | 0.01% | |
| 112 | INZYInozyme Pharma, Inc. | 106,999 | $1.8B | 0.01% | |
| 113 | PASGPassage Bio, Inc. | 117,161 | $1.6B | 0.01% | |
| 114 | —Affimed N.V. | 164,605 | $1.4B | 0.01% | |
| 115 | OYSTOyster Point Pharma, Inc. | 61,424 | $1.1B | 0.00% | |
| 116 | LPTXEURLeap Therapeutics, Inc. | 559,705 | $918.0M | 0.00% | |
| 117 | —Bellicum Pharmaceuticals, Inc. | 249,123 | $822.0M | 0.00% | |
| 118 | KZRKezar Life Sciences, Inc. | 139,676 | $758.0M | 0.00% | |
| 119 | —Frequency Therapeutics, Inc. | 55,555 | $553.0M | 0.00% | |
| 120 | —Syros Pharmaceuticals, Inc. | 65,497 | $357.0M | 0.00% |
PreviousPage 2 of 2